Does Blue Cross Blue Shield of Illinois Cover Cialis?

What Is Tadalafil and Why Does the Indication Matter for Coverage?

Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor approved by the FDA for three separate indications: erectile dysfunction (ED) under the brand Cialis, benign prostatic hyperplasia (BPH) under the brand Adcirca-related dosing pathway, and pulmonary arterial hypertension (PAH) under the brand Adcirca at 40 mg daily. Each indication carries a different ICD-10 code, and insurers, including BCBSIL, apply different coverage rules depending on which code appears on the claim. The FDA's original approval for tadalafil in ED dates to November 2003.

How PDE5 Inhibitors Work

Tadalafil blocks PDE5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in smooth-muscle cells. Higher cGMP levels relax arterial smooth muscle, increasing blood flow to the corpus cavernosum during sexual stimulation. The same mechanism explains its effect on the bladder neck and prostate in BPH. A 2022 review in the Journal of Sexual Medicine confirmed tadalafil's mean IIEF-EF domain score improvement of 6.5 to 8.0 points over placebo in men with organic ED.

Why the Indication Changes Coverage Outcomes

Insurers classify ED as a "lifestyle" condition under many benefit designs, which lets them exclude or restrict PDE5 inhibitors specifically for that diagnosis. BPH and PAH are classified as medical conditions with no similar carve-out. If your physician documents BPH (ICD-10 N40.1) alongside ED, the pharmacy claim has a stronger coverage basis on BCBSIL plans that restrict the N52 code alone. The American Urological Association's 2021 BPH guideline recommends PDE5 inhibitors as a monotherapy option for lower urinary tract symptoms, giving clinical weight to that diagnosis.

How BCBSIL Formularies Are Organized

Blue Cross Blue Shield of Illinois uses a tiered formulary system across its commercial, Marketplace, and Medicare Advantage products. Each tier carries a different cost-sharing structure. Knowing which tier tadalafil occupies on your specific plan is the first step to predicting your out-of-pocket cost.

Tier Definitions on Typical BCBSIL Commercial Plans

• Tier 1: Preferred generics. Lowest copay, usually $5 to $15.
• Tier 2: Non-preferred generics or preferred brand-name drugs. Copay typically $20 to $40.
• Tier 3: Non-preferred brands. Copay typically $45 to $75.
• Tier 4 / Specialty: High-cost drugs, often 20% to 33% coinsurance with no cap on some plans.

Generic tadalafil most commonly lands at Tier 2 on BCBSIL commercial plans when it is covered. Brand-name Cialis, if listed at all, sits at Tier 3 or Tier 4. The FDA's Orange Book confirms tadalafil has multiple generic manufacturers with AB-rated bioequivalence, meaning the generic is therapeutically interchangeable with brand Cialis.

Medicare Advantage and Part D Plans Through BCBSIL

Medicare Part D plans are prohibited from covering drugs used exclusively for ED under 42 CFR 423.100. Because tadalafil has the PAH and BPH indications, Part D plans may cover it when prescribed for those conditions. BCBSIL Medicare Advantage members prescribed tadalafil for BPH should confirm the formulary position with the plan's Medication Therapy Management team. CMS guidance on Part D exclusions is published at CMS.gov and cross-references the statutory exclusion list under Social Security Act §1927(d)(2).

Marketplace (ACA) Plans

BCBSIL Marketplace plans sold through the Illinois Health Insurance Marketplace are not required to cover ED medications under the ACA's essential health benefits framework. Coverage varies by metal tier (Bronze, Silver, Gold, Platinum) and plan year. For 2024 and 2025 plan years, most BCBSIL Silver and Gold Marketplace plans include generic tadalafil on the formulary when prescribed for BPH, but many exclude it for the ED diagnosis specifically.

Prior Authorization: When It Is Required and What to Expect

Prior authorization (PA) is a pre-approval process your physician must complete before BCBSIL will pay for the drug. PA for tadalafil is more common on the daily 5 mg dose (used for BPH or daily-use ED) than on the as-needed 10 mg or 20 mg doses.

Common PA Criteria on BCBSIL Plans

BCBSIL typically requires the prescribing physician to document:

1. A confirmed diagnosis of ED (ICD-10 N52.x) or BPH (ICD-10 N40.x).
2. That the patient has tried and failed, or has a contraindication to, a preferred Tier 1 alternative if one exists.
3. That the dose requested is appropriate for the indication (5 mg daily for BPH, 10 mg or 20 mg as needed for ED).

The FDA label for tadalafil specifies 5 mg once daily for BPH, with a maximum dose of 20 mg for ED as needed. Physicians who include this label language in the PA letter often see faster approvals.

How Long PA Takes

BCBSIL must respond to a standard PA request within 72 hours under Illinois Department of Insurance regulations. Urgent requests require a response within 24 hours. If your physician has not heard back within those windows, they can request a peer-to-peer review with a BCBSIL medical director.

What Happens If PA Is Denied

A PA denial is not final. BCBSIL must provide a written denial with the specific clinical reason. Your physician can submit additional clinical documentation or request a peer-to-peer call. If the internal appeal fails, Illinois law entitles enrollees to an external independent medical review. The Illinois Department of Insurance oversees this process under the Illinois Insurance Code, 215 ILCS 5/155.36.

Real Costs: What You Will Pay With and Without Coverage

Generic tadalafil's market price dropped sharply after patent expiration in 2018. Even without insurance, patients can access the drug at relatively low cost through discount programs. With BCBSIL coverage, the cost depends on tier and deductible status.

With BCBSIL Coverage (Post-Deductible)

| Dose | Quantity | Typical BCBSIL Tier 2 Copay | Typical BCBSIL Tier 3 Copay | |---|---|---|---| | Tadalafil 5 mg (daily) | 30 tablets | $15 to $35 | $40 to $65 | | Tadalafil 10 mg (as needed) | 6 tablets | $15 to $35 | $40 to $65 | | Tadalafil 20 mg (as needed) | 6 tablets | $15 to $35 | $40 to $65 | | Brand Cialis 20 mg | 30 tablets | Not typically covered | $80 to $150+ |

These figures represent post-deductible cost-sharing. If your plan has a $1,500 or $3,000 deductible that has not been met, you pay the negotiated rate, not the copay.

Without Coverage: Cash and Discount Options

Generic tadalafil 5 mg (30 tablets) retails for approximately $15 to $40 per month at major pharmacies using GoodRx or similar programs. A 2020 JAMA Internal Medicine analysis found that GoodRx prices were lower than insurance copays for 23% of common generic drugs, making it worth comparing even when you have coverage.

The Lilly Cares Foundation offers a patient assistance program for brand Cialis, though eligibility requires income below 400% of the federal poverty level and lack of prescription drug coverage. Program details are listed on the manufacturer's assistance program registry.

Erectile Dysfunction: The Clinical Evidence Behind Tadalafil

Understanding the evidence behind tadalafil helps physicians write stronger prior authorization letters and helps patients understand why their provider chose this drug over alternatives.

Key Clinical Trials

In a key Phase 3 trial (N=268) published in the European Urology journal, tadalafil 20 mg as-needed produced an IIEF-EF domain score improvement of 7.0 points compared to 1.0 point for placebo (P<0.001). That trial's PubMed record is available at PMID 12628618.

A separate 12-week trial (N=1,112) comparing tadalafil 5 mg daily versus placebo found that 59% of men in the tadalafil group achieved successful intercourse attempts versus 32% in the placebo group. PubMed PMID 16813906 documents this outcome.

Tadalafil vs. Sildenafil: Does BCBSIL Prefer One Over the Other?

Sildenafil (generic Viagra) is more widely listed as a Tier 1 preferred drug on BCBSIL plans than tadalafil. Some plans require a trial of sildenafil before approving tadalafil, because sildenafil has a longer generic history and lower acquisition cost for the plan. A 2019 meta-analysis in the Journal of Sexual Medicine (N=82 trials, 16,667 participants) found no statistically significant difference in IIEF-EF improvement between tadalafil and sildenafil overall, though tadalafil's 36-hour window of action was associated with higher patient preference scores.

If your BCBSIL plan requires a step-therapy trial of sildenafil first, your physician needs to document that attempt and its outcome before submitting the tadalafil PA.

BPH Coverage: A Stronger Path to Approval

Tadalafil 5 mg daily is FDA-approved for BPH with or without comorbid ED. For men who have both conditions, prescribing under the BPH indication often bypasses the ED-specific restrictions that BCBSIL plans apply.

Clinical Rationale Your Doctor Can Use

The AUA 2021 BPH guideline assigns a Grade B recommendation to PDE5 inhibitors for men with lower urinary tract symptoms (LUTS) and ED. That guideline is indexed on the AUA website and references 18 randomized controlled trials supporting tadalafil's effect on IPSS scores.

In a 12-week RCT (N=511), tadalafil 5 mg daily reduced International Prostate Symptom Score (IPSS) by 5.6 points from baseline versus 3.6 points for placebo (P<0.001). PubMed PMID 16813906 covers this outcome as well.

Documenting Both Diagnoses

When a patient has both BPH and ED, the physician's note should list N40.1 (BPH with LUTS) and N52.9 (ED, unspecified) in the problem list. The pharmacy claim should lead with the BPH code. This approach does not misrepresent the diagnosis. It accurately reflects the patient's clinical picture and reduces the probability of a coverage exclusion.

Pulmonary Arterial Hypertension: A Separate Coverage Track

For patients with PAH (ICD-10 I27.0), tadalafil 40 mg daily under the brand Adcirca (or generic equivalent) is typically covered as a specialty medication. BCBSIL generally requires documentation of WHO functional class II or III PAH and confirmation that the prescriber is a cardiologist or pulmonologist. The 2022 ESC/ERS PAH guidelines, referenced by the American Heart Association, list PDE5 inhibitors as a Class I recommendation for PAH management.

PAH coverage through BCBSIL is usually handled through a specialty pharmacy, not a retail pharmacy. The PA process is more intensive and may require submission of a right heart catheterization report confirming the diagnosis.

How to Check Your Specific BCBSIL Plan

No single answer applies to every BCBSIL plan. Here are the four steps to get a definitive answer for your specific coverage.

Step 1: Look Up the Formulary Online

Log in to your BCBSIL member portal at bcbsil.com. Under "Benefits and Coverage," select "Prescription Drug List" or "Formulary Search." Search for "tadalafil" and note the tier, quantity limits, and any PA or step-therapy flags.

Step 2: Call the Pharmacy Benefits Line

The member services number on the back of your BCBSIL card connects you to pharmacy benefit specialists who can confirm coverage, PA requirements, and your current deductible status in real time.

Step 3: Ask Your Pharmacist to Run a Test Claim

Before your physician submits the PA, ask your pharmacy to run a test claim with the tadalafil NDC and your BCBSIL group number. The response will show whether the claim is adjudicated, requires PA, or is outright excluded. This takes under two minutes and costs nothing.

Step 4: Have Your Physician Document Thoroughly

A prescription pad note does not replace thorough clinical documentation. Ask your physician to include the specific ICD-10 code, the clinical rationale for tadalafil over sildenafil if applicable, and any relevant comorbidities (BPH, cardiovascular disease, diabetes). Type 2 diabetes is a leading organic cause of ED, affecting an estimated 35% to 75% of men with the disease, according to a 2021 review in Diabetes Care.

Illinois State Law and Your Coverage Rights

Illinois has enacted specific consumer protections relevant to prescription drug coverage.

The Illinois Insurance Code and External Review

Illinois requires insurers to offer an external independent medical review for any adverse coverage determination. The external reviewer is selected by the Illinois Department of Insurance and is independent of BCBSIL. This process typically concludes within 45 days for standard reviews. The Illinois Department of Insurance publishes the external review request form at insurance.illinois.gov.

The Illinois Pharmacy Benefit Transparency Act

The Illinois Pharmacy Benefit Transparency Act (Public Act 101-0452) requires pharmacy benefit managers operating in Illinois to provide enrollees with formulary information and prohibits certain spread pricing practices. If BCBSIL's PBM is charging more than the negotiated rate at the pharmacy counter, you have grounds for a complaint with the Illinois Department of Insurance.

Gender Equity in Contraception Coverage

While not directly applicable to Cialis, Illinois's contraceptive equity law (Public Act 102-0228) established a precedent that Illinois courts and regulators have used to argue against discriminatory benefit designs. Some advocates have cited this law in challenging insurer policies that cover female sexual health drugs while excluding male ED treatments. The argument has not yet resulted in a mandate for ED coverage in Illinois, but it continues to inform policy discussions.

Telehealth Prescribing and BCBSIL Coverage

BCBSIL covers telehealth visits for a broad range of conditions, including ED, under both commercial and Marketplace plans. A telehealth visit with a BCBSIL-participating physician can generate a tadalafil prescription that flows through the same pharmacy benefit as an in-person prescription.

Under BCBSIL's telehealth benefit, the physician visit copay for a telehealth consultation is typically $0 to $30 on most Silver and Gold plans. The prescription then goes through the standard pharmacy benefit. This pathway is clinically appropriate: a 2021 systematic review in the Journal of Telemedicine and Telecare confirmed that telehealth management of ED produces equivalent patient satisfaction scores and prescription fulfillment rates compared to in-person care.

Illinois enacted permanent telehealth parity law (Public Act 102-0683) in 2022, requiring BCBSIL to reimburse telehealth visits at the same rate as in-person visits for covered services. This means you can start the tadalafil prescribing process from home without paying a higher out-of-pocket cost than an office visit.

What to Do When BCBSIL Denies Tadalafil Coverage

Denials happen. They are not always final. A structured response increases reversal rates substantially.

Step 1: Request the Denial Letter

BCBSIL must provide a written denial within 72 hours (standard) or 24 hours (urgent). The letter must state the specific clinical criteria used to make the denial decision.

Step 2: File an Internal Appeal

You have 180 days from the denial date to file an internal appeal with BCBSIL. Your physician should submit a letter of medical necessity that references the specific denial criteria and provides peer-reviewed literature supporting tadalafil for the documented diagnosis. A 2018 Annals of Internal Medicine study found that patients who appealed insurance denials succeeded in reversing the decision in approximately 39% to 59% of cases, depending on the insurer.

Step 3: Request External Review

If the internal appeal fails, request external independent review through the Illinois Department of Insurance. The external reviewer cannot be affiliated with BCBSIL. Their decision is binding on BCBSIL.

Step 4: Use Generic Tadalafil at Cash Price While Appealing

Generic tadalafil's low cash price means you do not need to go without medication while the appeal process runs. At $15 to $30 per month through discount programs, the out-of-pocket burden is manageable for most patients. The FDA's Drug Shortages and Generic Drug Competition data confirms tadalafil has more than eight approved generic manufacturers, sustaining competitive pricing.

Cost Comparison: Tadalafil vs. Other PDE5 Inhibitors on BCBSIL Plans

| Drug | Generic Available | Typical BCBSIL Tier | Cash Price (30-day supply) | |---|---|---|---| | Sildenafil (Viagra) | Yes, since 2017 | Tier 1 (most plans) | $10 to $25 | | Tadalafil (Cialis) | Yes, since 2018 | Tier 2 to Tier 3 | $15 to $40 | | Vardenafil (Levitra) | Yes | Tier 2 to Tier 3 | $20 to $50 | | Avanafil (Stendra) | No | Tier 4 or excluded | $300 to $450 |

Sildenafil's earlier generic entry gives it a price advantage and preferred formulary placement on most BCBSIL plans. If sildenafil is medically appropriate and your physician has no specific clinical reason to prefer tadalafil, starting with sildenafil may avoid a PA requirement entirely. The 2021 American Urological Association ED guideline states that all approved PDE5 inhibitors have similar efficacy, and selection should be based on patient preference, dosing schedule, and cost.

Key Takeaways for BCBSIL Members Seeking Tadalafil Coverage

Generic tadalafil is likely covered on your BCBSIL plan if your diagnosis is BPH or PAH. Coverage for the ED indication alone is less consistent and may require prior authorization or step-therapy through sildenafil first. Brand-name Cialis is rarely covered without a specific medical exception.

The single most impactful action you can take: ask your physician to document all applicable diagnoses (BPH, ED, or both) with specific ICD-10 codes before the prescription is sent to the pharmacy. A claim submitted with N40.1 has a higher probability of adjudicating without PA than a claim submitted with N52.9 alone on most BCBSIL commercial plans. If your prescriber practices through a telehealth platform covered by BCBSIL, the visit itself costs $0 to $30 and can generate a prescription the same day.